Olimpia Colombo
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Olimpia Colombo has a total of 6 co-authors. Here are the top co-authors by number of shared publications:
- Daniele Tognetto
Department of Medicine, Surgery and Health Sciences, University of Trieste, 34129 Trieste, Italy
2 shared publications - Gabriella Cirigliano
Eye Clinic, Department of Medical, Surgical Sciences and Health, University of Trieste, 34129 Trieste, Italy
2 shared publications - Marco Rocco Pastore
Eye Clinic, Department of Medical, Surgical Sciences and Health, University of Trieste, Trieste, Italy
2 shared publications - Serena Milan
Eye Clinic, Department of Medical Surgical Sciences and Health, University of Trieste, 34129, Trieste, Italy
2 shared publications - Silvia Rinaldi
Eye Clinic, Department of Medical, Surgical Sciences and Health, University of Trieste, 34127 Trieste, Italy
2 shared publications - Stefano Gouigoux
Eye Clinic, Department of Medical, Surgical Sciences and Health, University of Trieste, 34127 Trieste, Italy
2 shared publications
Latest Publications
- Open Access
- 19 December 2024
- Published by MDPI AG in Diagnostics
- Vol. 14 (24) , 2858
Brolucizumab for the Treatment of Diabetic Macular Edema: An Optical Coherence Tomography-Based Analysis
Objectives: The objectives of this study were to evaluate the structural and functional outcomes after the loading phase with brolucizumab in switched patients with diabetic macular edema (DME) and to identify potential predictive biomarkers of treatment response. Methods: A total of 28 eyes with DME, switched to brolucizumab, were retrospectively reviewed. Main outcomes during the follow-up period, up to 6 weeks after the fifth injection, included changes in best-corrected visual acuity (BCVA), central subfield thickness (CST), macular volume, subfoveal choroidal thickness, intraretinal and subretinal fluid (IRF and SRF), cyst dimension including maximal horizontal cyst diameter (MHCD), maximal vertical cyst diameter (MVCD), width-to-height ratio (WHR), foveal avascular zone (FAZ) dimension, and vessel density (VD). Results: At the last follow-up, BCVA was significantly improved (p = 0.003). Significant reduction of CST was demonstrated after each injection time point (p < 0.05), and a dry macula was detected in 64.3% of patients at the last follow-up. The WHR was 1.23 ± 0.46, and a negative correlation to final CST (p < 0.0001) was found. In FAZ and VD analysis, no significant variation was detected. At the last disease activity assessment, the treatment regimen was q12 in 64% of patients. Conclusions: Brolucizumab leads to anatomical and functional improvements in switched eyes affected by DME. WHR may represent a predictive biomarker of treatment response.
- 19 December 2024
- Published by MDPI AG in Diagnostics
- Vol. 14 (24) , 2858
Open AccessBrolucizumab for the Treatment of Diabetic Macular Edema: An Optical Coherence Tomography-Based Analysis
Objectives: The objectives of this study were to evaluate the structural and functional outcomes after the loading phase with brolucizumab in switched patients with diabetic macular edema (DME) and to identify potential predictive biomarkers of treatment response. Methods: A total of 28 eyes with DME, switched to brolucizumab, were retrospectively reviewed. Main outcomes during the follow-up period, up to 6 weeks after the fifth injection, included changes in best-corrected visual acuity (BCVA), central subfield thickness (CST), macular volume, subfoveal choroidal thickness, intraretinal and subretinal fluid (IRF and SRF), cyst dimension including maximal horizontal cyst diameter (MHCD), maximal vertical cyst diameter (MVCD), width-to-height ratio (WHR), foveal avascular zone (FAZ) dimension, and vessel density (VD). Results: At the last follow-up, BCVA was significantly improved (p = 0.003). Significant reduction of CST was demonstrated after each injection time point (p < 0.05), and a dry macula was detected in 64.3% of patients at the last follow-up. The WHR was 1.23 ± 0.46, and a negative correlation to final CST (p < 0.0001) was found. In FAZ and VD analysis, no significant variation was detected. At the last disease activity assessment, the treatment regimen was q12 in 64% of patients. Conclusions: Brolucizumab leads to anatomical and functional improvements in switched eyes affected by DME. WHR may represent a predictive biomarker of treatment response.
- Open Access
- 19 November 2024
- Published by MDPI AG in Preprints.org
Brolucizumab for the Treatment of Diabetic Macular Edema: An Optical Coherence Tomography – Based Analysis
Objectives : to evaluate the structural and functional outcomes after the loading phase with Brolucizumab in switched patients with diabetic macular edema (DME), and to identify potential predictive biomarkers of treatment response. Methods: A total of 28 eyes with DME, switched to Brolucizumab, were retrospectively reviewed. Main outcomes during the follow-up period, up to 6 weeks after the fifth injection, included changes in best-corrected visual acuity (BCVA), central subfield thickness (CST), macular volume, subfoveal choroidal thickness, intraretinal and subretinal fluid (IRF, SRF), cyst dimension including maximal-horizontal-cyst-diameter (MHCD), maximal-vertical-cyst-diameter (MVCD), width to height ratio (WHR), foveal avascular zone (FAZ) dimension, and vessel density (VD). Results: At the last follow-up, BCVA was significantly improved (p=0.003). Significant reduction of CST was demonstrated after each injection time point (p<0.05), and a dry macula was detected in 64.3% of patients at the last follow-up. The WHR was 1.23 ± 0.46 and a negative correlation to final CST (p<0.0001) was found. In FAZ and VD analysis, no significant variation was detected. At the last disease activity assessment, the treatment regimen was q12 in 64% of patients . Conclusion: brolucizumab leads to anatomical and functional improvements in switched eyes affected by DME. WHR may represent a predictive biomarker of treatment response.
- 19 November 2024
- Published by MDPI AG in Preprints.org
Open AccessBrolucizumab for the Treatment of Diabetic Macular Edema: An Optical Coherence Tomography – Based Analysis
Objectives : to evaluate the structural and functional outcomes after the loading phase with Brolucizumab in switched patients with diabetic macular edema (DME), and to identify potential predictive biomarkers of treatment response. Methods: A total of 28 eyes with DME, switched to Brolucizumab, were retrospectively reviewed. Main outcomes during the follow-up period, up to 6 weeks after the fifth injection, included changes in best-corrected visual acuity (BCVA), central subfield thickness (CST), macular volume, subfoveal choroidal thickness, intraretinal and subretinal fluid (IRF, SRF), cyst dimension including maximal-horizontal-cyst-diameter (MHCD), maximal-vertical-cyst-diameter (MVCD), width to height ratio (WHR), foveal avascular zone (FAZ) dimension, and vessel density (VD). Results: At the last follow-up, BCVA was significantly improved (p=0.003). Significant reduction of CST was demonstrated after each injection time point (p<0.05), and a dry macula was detected in 64.3% of patients at the last follow-up. The WHR was 1.23 ± 0.46 and a negative correlation to final CST (p<0.0001) was found. In FAZ and VD analysis, no significant variation was detected. At the last disease activity assessment, the treatment regimen was q12 in 64% of patients . Conclusion: brolucizumab leads to anatomical and functional improvements in switched eyes affected by DME. WHR may represent a predictive biomarker of treatment response.